Miguel Guelfand, MD

• Section Head, Pediatric General and Thoracic Surgery, Cleveland Clinic Children’s Hospital (2023–Present)
• Full Professor of Surgery, Lerner College of Medicine, Case Western Reserve University (2023–Present)
• Full Professor of Pediatric Surgery, University of Chile (2001–Present)
• Program Director of Pediatric Surgery, University of Chile (2010–2017)
• Professional Society Memberships and Leadership Roles
• Past President, International Pediatric Endosurgery Group (IPEG) (2021–2022)
• Counselor, International Pediatric Live Surgery Group (2024–Present)
• Member, American College of Surgeons (2022–Present)
• Member, Chilean Pediatric Surgical Association (2005–Present)
• Member, International Pediatric Endosurgery Group (IPEG) (2005–Present)
• Editorial Board Memberships
• Journal of Laparoendoscopic & Advanced Surgical Techniques (Editorial Board Member, 2011–Present)
• Journal of Pediatric Surgery (Editorial Board Member, 2020–Present)
• Surgical Innovation (Editorial Board Member, 2023–Present)
• Medical License Distinction
• Recipient of a Conceded Eminence Medical License in the United States, awarded in recognition of his internationally acknowledged expertise in pediatric surgery and minimally invasive neonatal techniques.

President of the Republic of Chile Award for International Studies
Government of Chile, 1999–2000
Prestigious national scholarship awarded for outstanding academic achievement and international training in pediatric surgery.

Biomedical Advanced Studies Foundation Award
University of Chile, 2002
Recognition for contributions to surgical education and clinical innovation in pediatric surgery.

Nominee for the David Vogt Award 2025
Cleveland Clinic,
Nominated for excellence in surgical leadership, innovation, and commitment to advancing pediatric patient care.

Conceded Eminence Medical License – United States
Awarded in recognition of Dr. Guelfand’s internationally recognized expertise in pediatric and neonatal minimally invasive surgery, enabling medical practice without traditional licensure pathways due to exceptional qualifications.

See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.

As of 2026-01-01, Dr. Guelfand has reported the financial relationships with the companies listed below.

Consulting and/or Speaking. Dr. Guelfand receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Stryker Corporation

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.